期刊文献+

两性霉素B/聚乙二醇-聚谷氨酸苄酯纳米球溶血毒性的研究 被引量:6

Haemolytic Evaluation of Amphotericin B Loaded PEG-PBLG Nanospheres
下载PDF
导出
摘要 目的 :考察两性霉素B/聚乙二醇 聚谷氨酸 (AmB/PEG PBLG)纳米球是否能降低AmB的溶血毒性。方法 :超微透析法制备AmB/PEG PBLG纳米药球 ,用紫外分光光度法测定样品的溶血率。结果 :AmB/PEG PBLG纳米药球平均粒径 14 2 1nm ,载药量 2 7 5 5 % ;溶血率从低到高依次为 :PEG PBLG空白纳米球、脱氧胆酸钠、AmB/PEG PBLG纳米药球、AmB注射液。结论 :AmB/PEG PBLG纳米药球能有效降低AmB的溶血毒性。 AIM:To investigate whether the amphotericin B (AmB) loaded PEG-PBLG nanospheres decreased the hemolytic toxicity.METHOD:AmB loaded PEG-PBLG nanospheres were prepared by diafiltration method.The haemolytic percentage was measured by UV.RESULT:The mean particle size was 142.1 nm and loading drug content was 27.55%.The haemolytic percentage from low to high were PEG-PBLG nanospheres,sodium deoxycholate,AmB loaded PEG-PBLG nanospheres,AmB injection.CONCLUSION:PEG-PBLG nanospheres are promising carriers to decrease the haemolytic toxicity of AmB.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2004年第3期263-266,共4页 Journal of China Pharmaceutical University
关键词 两性霉素B 聚乙二醇 聚谷氨酸苄酯 纳米药球 溶血毒性 AmB PEG PBLG Nanospheres Hemolytic toxicity
  • 相关文献

参考文献4

  • 1Kim JC,Lee EO,Kim JY,et al.Hemolytic and antifungal activity of liposome- entrapped amphotericin B prepared by the precipitation method[J].Pharm Dev Technol,1997,2(3):275-284.
  • 2Neal JC,Stolnik S,Schacht E,et al.In vitro displacement by rat serum of absorbed radiolabeled polocamer and poloxamine copolymer from model and biodegradable nanospheres[J].J Pharm Sci,1998,87(10):1242-1248.
  • 3潘仕荣,施锋,黄宁芳,周群,林在峰,易武.白氨酸-谷氨酸甲酯-谷氨酸共聚物的合成研究[J].生物医学工程学杂志,1997,14(2):101-104. 被引量:10
  • 4Jeong YI,Cheon JB,Kim SH,et al.Clonazepam release from core-shell type nanoparticles in vitro[J].J control Rel,1998,51(2-3):169-178.

二级参考文献3

共引文献9

同被引文献83

  • 1林宏英,陆晓燕,唐宁,梁伟.长春新碱PEG-PE胶束的制备及其对乳腺癌细胞生长的抑制[J].生物化学与生物物理进展,2006,33(8):769-774. 被引量:14
  • 2陈裕充,温海.两性霉素B及其脂质体的抗真菌机制[J].中国真菌学杂志,2006,1(5):312-314. 被引量:31
  • 3邵英,路来金,荣莉,彭维海,蓝珊珊,张舵.聚L-乳酸/聚L-乳酸接枝的羟基磷灰石复合材料的生物相容性[J].吉林大学学报(医学版),2007,33(1):57-60. 被引量:14
  • 4吴瑞珍,谭瑞珠,梁超莲.两性霉素B常见不良反应的临床观察与护理[J].护理研究(下旬版),2007,21(1):246-247. 被引量:6
  • 5GIBBS W J, DREW R H, PERFECT J R. Liposomal amphoterlcin B: clinical experience and perspectives[ J]. Eepert Rev Anti Infect Ther, 2005, 3(2): 167-181.
  • 6TANGGZ WANGHY SHIXX.Introduction foreign AraB lipoid preparations.上海医药,2005,26(6):274-276.
  • 7BARRETT J P, VARDULAKI K A, CONLON C, et al. A systematic review of the antifungal effectiveness and tolerability of amphoterlcin B formulations [ J ] . Clin Ther, 2003, 25 ( 5 ) : 1295-1320.
  • 8GOLENSER J, DOMB A. New formulations and derivatives of amphotericin B for treatment of leishmaniasis [ J ]. Mini Rev Med Chem, 2006, 6(2) : 153-162.
  • 9SACHS-BARRABLE K, LEE S D, WASAN E K, et al. Enhancing drug absorption using lipids : A case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections[ J]. Adv Drug Deliv Rev, 2008, 60(6): 692-701.
  • 10CHOI K C, BANG J Y, KIM P I, et al. Amphotericin B-incorporated polymeric micelles composed of poly (d, 1-lactide-co-glycolide)/dextran graft copolymer[ J]. Int J Pharm, 2008, 355 ( 1-2 ) : 224-230.

引证文献6

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部